Canary Medical and BioScience Managers form CHARM Informatics

BioScience Managers commits AUS$10M to new joint venture with Canary Medical to serve as a platform to collect and monetize data from implantable and wearable medical devices. Vancouver, British Columbia, Aug 1, 2017 – Canary Medical (Canary) is pleased to announce the formation of CHARM Informatics Pty Ltd (CHARM), in collaboration with BioScience Managers Pty Ltd […]

Adherium Appoints New CEO to Drive Global Growth

9 June 2017:link here Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the […]

Dr Michael S. Perry appointed Avita Medical CEO

US-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive – Prior SVP & Chief Scientific Officer of Business Development and previous Chief Scientific Officer of Novartis’ Cell & Gene Therapy Unit • Adam Kelliher […]

AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

CATEGORY: Featured Wednesday, May 31, 2017 4:05 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D. as Chief Executive Officer, […]

Avita Medical’s Board show confidence in company by taking payment in shares

Directors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 23 May 2017 —link here The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH; OTCQX: AVMXY), have shown a strong […]

Avita Medical Announces Positive Results from Pivotal Trial

Highlights • Co-primary endpoints achieved in pivotal trial deploying ReCell® in patients with severe burns • Positive results also seen in another supportive trial • Company on-track to file a PMA with the U.S. Food & Drug Administration in mid-2017 • Avita primed to execute on U.S. commercialization strategy as early as Q2 2018 Valencia, […]

AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights

Monday, May 15, 2017 4:01 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In parallel, we are seeking opportunities to advance our chronic rhinosinusitis (CRS) and preclinical cystic fibrosis (CF) programs, potentially through partnerships and/or non-dilutive funding.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development […]

Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards

15/05/2017 – link here Adherium have come out on top at this year’s Hi-Tech Awards, claiming the coveted Hi-Tech Hardware Product award. Over 900 people attended the awards ceremony, which celebrates the successes of New Zealand hi-tech companies across 13 categories. In selecting Adherium as Most Innovative Hi-Tech Hardware Product, the international judges said, “Adherium has […]

Avita Medical initiates legal proceedings to cancel Renovacare patent

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against US Patent No. 9,610,430 (the ‘430 patent) owned by Renovacare Sciences Corp., as […]

AmpliPhi Biosciences Announces Closing of Public Offering

Wednesday, May 10, 2017 5:29 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its previously announced underwritten public offering. Total proceeds […]